Browsing Tag
TAK-279
2 posts
Takeda’s zasocitinib shows high clearance rates at difficult psoriasis sites
Scalp and palmoplantar clearance rates approached 70% to 77%, but regulatory review, safety labelling and market access will determine the commercial impact.
Takeda’s TAK-279 meets primary endpoint in Phase 2b trial for psoriatic arthritis
Takeda Pharmaceutical Company announced positive results from its Phase 2b clinical trial for TAK-279, an investigational oral TYK2…